Sartorius AG Vorz-Inhaber-Akt ohne Stimmrecht
SRT3: XETR (DEU)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| €998.00 | Xhj | Flbtqfyjl |
Sartorius Earnings: Results Slightly Disappointing but Midterm Guidance in Line; Valuation Unchanged
/s3.amazonaws.com/arc-authors/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
Wide-moat companies Sartorius AG and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB, reported preliminary full-year results that were slightly below expectations. More significantly, the companies provided midterm guidance out until 2028 that were in line with expectations. We maintain our fair value estimates of EUR 295 per Sartorius AG preference share and EUR 240 per SSB share, and view the current prices as fairly valued.